Introduction
Patients and methods
Patients
Planning and treatment guidelines
Statistics
Results
Study population and characteristics
Characteristic | IR RT alone (n = 177) | IR RT+ ADT (n = 196) |
P
|
---|---|---|---|
Age (mean ± SD, years) | 72 ± 5.34 | 72 ± 5.85 | 0.934 |
Pretreatment PSA (ng/mL) | 7.88 ± 3.55 | 9.34 ± 3.97 | 0.001> |
Fiducials implant % (n) | 71.8 (127) | 65.3 (128) | 0.181 |
Gleason score % (n) | 0.257 | ||
5 or 6 | 19.8 (35) | 15.8 (31) | |
7 (3 + 4) | 52.5 (93) | 49.0 (96) | |
7 (4 + 3) | 27.7 (49) | 35.2 (69) | |
T- stage % (n) | 0.074 | ||
T1 | 31.4 (50) | 23.4 (37) | |
T2a-b | 64.8 (103) | 67.7 (107) | |
T2c | 3.8 (6) | 8.9 (14) | |
No. IR risk factors % (n) | 0.001> | ||
1 | 65.0 (115) | 42.6 (83) | |
2 | 31.1 (55) | 48.7 (95) | |
3 | 4.0 (7) | 8.7 (17) | |
RT treatment modality % (n) | 0.929 | ||
3D | 17.2 (29) | 15.7 (29) | |
IMRT | 23.1 (39) | 23.8 (44) | |
VMAT | 59.8 (101) | 60.5 (112) | |
RT lymph-nodes % (n) | 2.8 (5) | 10.7 (21) | 0.003 |
Positive biopsy cores % (mean ± SD) | 45.33 ± 25.56 | 52.56 ± 27.61 | 0.017 |
Charlson comorbidity index | 0.774 | ||
2 | 49.4 (80) | 52.0 (93) | |
3 | 16.7 (27) | 14.0 (25) | |
4≤ | 34.0 (55) | 34.1 (61) | |
Months follow-up | 57.6 ± 36.9 | 54.3 ± 37.4 | 0.383 |
Patterns of treatment failure and outcome
Predictors of biochemical failure in patients treated with RT alone
Characteristic | Covariate type | Number at risk | Cumulative probability of biochemical failure | Univariate analysis | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
HR | P | 95% C.I. | HR | P | 95% C.I. | ||||||
Lower | Upper | Lower | Upper | ||||||||
Age ≤ 70 years | Categorical | 56 | 17.9% | 3.32 | 0.018 | 1.226 | 8.464 | 3.06 | 0.025 | 1.153 | 8.138 |
Pretreatment PSA (ng/mL) | Continuous | 177 | 1.03 | 0.684 | 0.899 | 1.176 | |||||
Gleason score | Categorical | 177 | |||||||||
5 or 6 | 35 | 5.7% | 1 | reference | |||||||
7 (3 + 4) | 93 | 6.5% | 1.16 | 0.852 | 0.235 | 5.772 | 1.42 | 0.667 | 0.285 | 7.128 | |
7 (4 + 3) | 49 | 18.4% | 3.16 | 0.141 | 0.685 | 14.656 | 3.32 | 0.125 | 0.717 | 15.383 | |
T- stage T2b to T2c | Categorical | 61 | 11.5% | 1.73 | 0.280 | 0.641 | 4.664 | ||||
No. IR risk factors | Categorical | 177 | |||||||||
1 | 115 | 8.7% | 1 | reference | |||||||
2 | 55 | 10.9% | 1.76 | 0.278 | 0.635 | 4.856 | |||||
3 | 7 | 14.3% | 2.87 | 0.319 | 0.361 | 22.750 | |||||
Positive biopsy cores (%) | Continuous | 154 | 1 | 0.917 | 0.981 | 1.022 | |||||
Charlson comorbidity index | Categorical | 162 | |||||||||
2 | 69 | 11.6% | 1 | reference | |||||||
3 | 27 | 0% | 0.00 | 0.977 | 0.000 | 0.000 | |||||
≥4 | 49 | 10.9% | 0.72 | 0.836 | 0.309 | 2.261 |